Association between reversal of multidrug resistance by methyl jasmonate and P-glycoprotein ATPase activity in

Related Experiment Video

Updated: May 9, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Chang-Fa Wang1, Ya-Qin Wang, Fei-Zhou Huang

  • 1Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China. wangchangfa1978@hotmail.com

The Journal of International Medical Research
|July 23, 2013
PubMed
Abstract

Insights

Methyl jasmonate enhances chemotherapy effectiveness against multidrug-resistant hepatocellular carcinoma. This study shows methyl jasmonate combined with the FAP regimen significantly increases survival time in mice, offering a new strategy for cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Hepatocellular carcinoma (HCC) frequently develops multidrug resistance (MDR).
  • Multidrug resistance limits the efficacy of standard chemotherapy regimens.
  • Identifying novel agents to overcome MDR in HCC is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the potential of methyl jasmonate to reverse multidrug resistance in hepatocellular carcinoma.
  • To evaluate the synergistic effects of methyl jasmonate with a standard chemotherapy regimen (FAP) in a mouse model of HCC.

Main Methods:

  • Multidrug resistant H22 (H22/FAP) cells were established in vitro.
  • Cytotoxicity was assessed using the MTT assay.
  • In vivo efficacy was determined in BALB/c mice, measuring survival time and P-gp ATPase activity.

Main Results:

  • Methyl jasmonate significantly potentiated the cytotoxicity of the FAP regimen against H22/FAP cells.
  • Combination therapy with methyl jasmonate and FAP markedly increased mouse survival rates.
  • Methyl jasmonate was observed to increase P-glycoprotein (P-gp) ATPase activity.

Conclusions:

  • Methyl jasmonate demonstrates potential as an adjuvant therapy to overcome MDR in hepatocellular carcinoma.
  • The combination of methyl jasmonate with the FAP regimen represents a promising novel strategy for HCC treatment.
  • Further research into methyl jasmonate's mechanism in reversing MDR is warranted.
Keywords:
ATPase activityH22 cell lineH22/FAP cell lineMethyl jasmonatehepatocellular carcinomamultidrug resistancepermeability (P)-glycoprotein

More Related Videos

Gap Junctional Intercellular Communication: A Functional Biomarker to Assess Adverse Effects of Toxicants and Toxins, and Health Benefits of Natural Products05:27

Gap Junctional Intercellular Communication: A Functional Biomarker to Assess Adverse Effects of Toxicants and Toxins, and Health Benefits of Natural Products

Published on: December 25, 2016

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...